Emerging in the landscape of obesity therapy, retatrutide presents a different method. Beyond many existing medications, retatrutide functions as a twin agonist, concurrently engaging both glucagon-like peptide-1 (GLP-1) and glucose-responsive insulinotropic hormone (GIP) receptors. The simultaneous stimulation promotes various helpful effects, inc